RxDoctor Payments Data

Tasha Leonard

Nurse Practitioner · Houston, TXNPI 1326664020

Payments from drug & device makers

$1,677in general payments, 2019–2025

Across 68 payments — averaging $24.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$312
  • E.r. Squibb & Sons, L.L.C.$233
  • Merck$188
  • Pfizer$145
  • Irhythm Technologies, Inc.$121
  • Edwards Lifesciences$105
  • plus $573 from 16 others

What the payments were for

  • Food & beverage$1,677100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,677 in reported general payments places this provider in the 80th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$14,899
Medicare patients
124
Services billed
318

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban200$207,118
XareltoRivaroxaban82$95,578
EntrestoSacubitril/Valsartan26$26,632
Flecainide Acetate103$5,571
Metoprolol Succinate379$5,245
Clonidine17$4,007
Losartan Potassium216$2,805
Atorvastatin Calcium243$2,785
Nebivolol Hcl40$2,673
Carvedilol279$2,593
Potassium Chloride84$1,677
Amlodipine Besylate224$1,677
Nifedipine ErNifedipine61$1,606
Amiodarone Hcl30$1,307
ClopidogrelClopidogrel Bisulfate77$1,127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$145$207,118200 claims
Johnson & JohnsonXarelto$67$95,57882 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →